(Q35076846)

6 August 2017

1 reference

title

Epstein-Barr virus-recent advances (English)

1 reference

6 August 2017

0 references

Karen F Macsween

1

1 reference

6 August 2017

Dorothy H Crawford

series ordinal

2

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Lancet Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

131-140

1 reference

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Detection of Epstein-Barr virus in invasive breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Association of Epstein-Barr virus with thymic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Biology and disease associations of Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

EBV persistence in memory B cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Primary Infection with Epstein-Barr Virus in Infants in the United States: Clinical and Serologic Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Intrafamilial transmission of Epstein-Barr virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Primary epstein-barr virus infections in African infants. II. Clinical and serological observations during seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Prevalence, incidence and persistence of EB virus antibody in young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Excretion of the Epstein-Barr Virus from the Genital Tract of Men

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

A second site for Epstein-Barr virus shedding: the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Sexual history and Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Association of EB-virus infection with the post-perfusion syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Geographical prevalence of two types of Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Cell-switching and kissing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

The ins and outs of EBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Structure of the crypt epithelium in human palatine tonsils.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

A novel form of Epstein-Barr virus latency in normal B cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus: exploiting the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

THE INCUBATION PERIOD OF INFECTIOUS MONONUCLEOSIS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Hepatosplenomegaly in infectious mononucleosis, assessed by ultrasonic scanning

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

CUTANEOUS MANIFESTATIONS OF INFECTIOUS MONONUCLEOSIS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Ampicillin rash in children. Relationship to penicillin allergy and infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Limitations of available tests for diagnosis of infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Persistent Falsely Positive Rapid Tests for Infectious Mononucleosis: Report of Five Cases with Four–Six-year Follow-up Data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Systemic lupus erythematosus presenting as infectious mononucleosis with a false positive monospot test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus and human diseases: recent advances in diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Interventions for the treatment and management of chronic fatigue syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Acyclovir and Epstein--Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Acyclovir treatment in infectious mononucleosis: a clinical and virological study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working Group on Steroid Use, Antimicrobial Agents Committee, Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Steroids for airway problems in glandular fever.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Serum Levels of Lymphokines and Soluble Cellular Receptors in Primary Epstein-Barr Virus Infection and in Patients with Chronic Fatigue Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

The chronic mononucleosis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Fatal infectious mononucleosis in a family

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X-linked recessive progressive combined variable immunodeficiency (Duncan's disease)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X-linked lymphoproliferative disease: twenty-five years after the discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X-linked lymphoproliferative syndrome registry report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X linked lymphoproliferative disease in a United Kingdom family

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Treatment of EBV-induced lymphoproliferative disorder with epipodophyllotoxin VP16-213

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X-linked lymphoproliferative disease: three atypical cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Lymphocytic vasculitis in X-linked lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

A novel receptor involved in T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Viruses and Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Reed-Sternberg-like cells in infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

An immunohistochemical analysis of Reed-Sternberg-like cells in posttransplantation lymphoproliferative disorders: the possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin's disease and Reed-Sternberg-like cells in non-Hodgkin's lym

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

AIDS-associated non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus in AIDS-related primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

HIV-associated Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Oral hairy leukoplakia in a HIV-negative renal transplant patient: a marker for immunosuppression?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Oral hairy leukoplakia in an HIV-negative renal transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Oral hairy leukoplakia in a patient with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Regression of oral hairy leukoplakia after orally administered acyclovir therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900543-7

7 January 2021

10.1016/S1473-3099(03)00543-7

Identifiers

DOI

1 reference

6 August 2017

1 reference